Navigation Links
BioMarin Appoints Dr. Gordon Vehar, Vice President of Research

NOVATO, Calif., Jan. 28 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today the appointment of Dr. Gordon Vehar as Vice President of Research. Former Vice President of Research and Development for Raven Biotechnologies, Dr. Vehar is the inventor of numerous biotechnology patents and the recipient of a collection of prestigious scientific awards including two Distinguished Inventor of the Year Awards from Intellectual Property Owners, Inc.

"We are very pleased to welcome Dr. Vehar to BioMarin. He brings with him extraordinary research and drug development experience and his contributions will substantially bolster our efforts to grow our early pipeline at BioMarin," said Dr. Emil Kakkis, Senior Vice President and Chief Medical Officer.

Dr. Vehar also served in various roles throughout a 20-year tenure with Genentech, including Director of Cardiovascular Research and Staff Scientist for Cardiovascular Research and Protein Chemistry. Also at Genentech, he served as Project Team Leader on various drug discovery and development projects, which yielded four marketed products. He is the recipient of the Murray Thelin Award for Outstanding Research presented by the National Hemophilia Foundation, the Inventor of the Year Award given by Intellectual Property Owners, Inc., for the human tissue plasminogen activator (t-PA) patent for the treatment of heart attacks and stroke, and the Distinguished Inventor of the Year Award from Intellectual Property Owners, Inc. for the patent on recombinant Factor VIII, a genetically engineered clotting factor enabling production of a therapeutic product for treating hemophilia A. Dr. Vehar has served on the Scientific Advisory Board for the Oklahoma Center for Molecular Medicine, he is an inventor with 37 issued patents and is the author of more than 35 publications. Dr. Vehar received a Ph.D. from the University of Cincinnati Medical School.

Dr. Vehar joins two other new executives recently appointed to BioMarin: Steve Glass, Vice President and General Manager of European Operations and Lewis Chapman, Vice President of Global Marketing. Recent internal leadership appointments include Luisa Bigornia, Vice President of Intellectual Property, and Dr. Charles O'Neill, Vice President of Pharmacological Sciences.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(TM) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of PKU. For additional information, please visit Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about the development and commercialization of products; actions by regulatory authorities; and statements regarding the development of its product candidates. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: the results and timing of current and planned clinical trials; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2006 Annual Report on Form 10-K. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin(R) and Naglazyme(R) are registered trademarks of BioMarin Pharmaceutical Inc.


Investors: Media:

Eugenia Shen Susan Berg

BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc.

+ 1 415 506 6570 + 1 415 506 6594

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
2. BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease
3. BioMarin to Present at the Rodman & Renshaw 9th Annual Healthcare Conference
4. BioMarin to Present at the BioCentury NewsMakers Conference
5. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
6. Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors
7. Lentigen Appoints Tim Ravenscroft as Chief Executive Officer
8. Cylene Pharmaceuticals Appoints Kenna Anderes, Ph.D. as Vice President of Cancer Biology
9. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
10. Alba Therapeutics Appoints Wendy Perrow as its Vice President, Marketing and Alliance Management
11. Stereotaxis Appoints David Burkhardt, M.D. as Chief Medical Officer
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and Zachary ... in their initial angel funding process. Now, they are paying it forward to ... early stage investments in the microbiome space. In this, they join other ...
(Date:11/24/2015)... VANCOUVER , Nov. 24, 2015 /CNW/ - iCo ... ICOTF), today reported financial results for the quarter ... are expressed in Canadian dollars and presented under ... the United States ," said Andrew ... "These advancements regarding iCo-008 are not only value ...
(Date:11/24/2015)... 24, 2015 --> ... report "Oligonucleotide Synthesis Market by Product & Services (Primer, ... Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic ... the market is expected to reach USD 1,918.6 Million ... a CAGR of 10.1% during the forecast period. ...
(Date:11/24/2015)...  Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that its Annual General ... a.m. Israel time, at the law offices of ... 36 th Floor, Tel Aviv, Israel . ... Izhak Tamir to the Board of Directors; , election ... , approval of an amendment to certain terms of options granted to ...
Breaking Biology Technology:
(Date:10/29/2015)... Calif. , Oct. 29, 2015  The J. ... new report titled, "DNA Synthesis and Biosecurity: Lessons Learned ... the Department of Health and Human Services guidance for ... in 2010. --> ... it also has the potential to pose unique biosecurity ...
(Date:10/29/2015)... ANN ARBOR, Mich. , Oct. 29, 2015 ... with Eurofins Genomics for U.S. distribution of its ... DNA-seq kit and Rubicon,s new ThruPLEX Plasma-seq ... DNA to enable the preparation of NGS libraries ... in plasma for diagnostic and prognostic applications in ...
(Date:10/29/2015)... 29, 2015 NXTD ) ... focused on the growing mobile commerce market and ... StackCommerce, a leading marketplace to discover and buy ... smart wallet on StackSocial for this holiday season. ... the "Company"), a biometric authentication company focused on ...
Breaking Biology News(10 mins):